Volume 8, Issue 1, March 2020, Page: 1-8
Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology
Vasyl Beniuk, Department of Obstetrics and Gynecology, Bogomolets National Medical University, Kyiv, Ukraine
Vadym Goncharenko, Department of Obstetrics and Gynecology, Bogomolets National Medical University, Kyiv, Ukraine
Andrii Kurchenko, Department of Clinical Immunology, Allergology and Medical Genetics, Bogomolets National Medical University, Kyiv, Ukraine
Oleksii Tatskyy, International Institute of Biotherapy, Kyiv, Ukraine
Sergii Konovalenko, Department of Monitoring of Tumor Process and Therapy Design, RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
Svitlana Vintoniuk, City Maternity Hospital, Ivano-Frankivsk, Ukraine
Sergii Melnikov, Department of Restorative Urology and Innovative Technologies, Institute of Urology AMS of Ukraine, Kyiv, Ukraine
Kamil Nurimanov, Department of Sexology and Andrology, Institute of Urology AMS of Ukraine, Kyiv, Ukraine
Sergii Podpriatov, Center for Electric Welding Surgery and New Surgical Technologies, Kyiv, Ukraine
Received: Feb. 7, 2020;       Accepted: Feb. 21, 2020;       Published: Mar. 2, 2020
DOI: 10.11648/j.iji.20200801.11      View  409      Downloads  149
Abstract
The article provides evidence of clinical experience with the use of Arecur® for the treatment of endocervicitis and dysplasia of the cervix, endometrioma, chronic bacterial prostatitis, and for postoperative rehabilitation in patients after removal of hemorrhoids. Arecur® contains exogenous peptides of natural origin – anti-infective proteins of the group of defensins and RJP-1 and has antibacterial, antiviral, anti-inflammatory and antitumor activity. In the study groups, in which Arecur® was assigned to the patients, were reported significantly better clinical efficacy results. The ability of exogenous peptides to mobilize T-lymphocytes to identify and destroy infected and atypical cells determines the elimination of human papilloma virus and creates the conditions for reducing the risk of malignant cell transformation of cervical canal. Arecur®, by enhancing the immune supervision of ectopic endometrial cells, promotes regression of clinical symptoms and prolongation of inter-relapsing intervals in patients with endometriosis. In chronic bacterial prostatitis Arecur® increases the efficiency of etiotropic and symptomatic therapy. After surgical removal of hemorrhoid lesions, Arecur® provides more positive dynamics of rehabilitation, improves patients' quality of life and prevents complications. The obtained results allow us to reasonably recommend Arecur® as a medicine for anti-recurrent immunocorrection in gynecology, andrology and proctology.
Keywords
Anti-Recurrent Immunocorrection, Exogenous Peptides, Arecur, Endocervicitis, Dysplasia, Human Papilloma Virus, Chlamydia, Endometrioma, Prostatitis, Hemorrhoids
To cite this article
Vasyl Beniuk, Vadym Goncharenko, Andrii Kurchenko, Oleksii Tatskyy, Sergii Konovalenko, Svitlana Vintoniuk, Sergii Melnikov, Kamil Nurimanov, Sergii Podpriatov, Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology, International Journal of Immunology. Vol. 8, No. 1, 2020, pp. 1-8. doi: 10.11648/j.iji.20200801.11
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Sun CQ, Arnold RS, Hsieh CL, Dorin JR, Lian F, Li Z, Petros JA. Discovery and mechanisms of host defense to oncogenesis: targeting the β-defensin-1 peptide as a natural tumor inhibitor. Cancer Biol Ther. 2019; 20 (6): 774-786.
[2]
Parvy JP, Yu Y, Dostalova A, Kondo S, Kurjan A, Bulet P, Lemaître B, Vidal M, Cordero JB. The antimicrobial peptide defensin cooperates with tumour necrosis factor to drive tumour cell death in Drosophila. Elife. 2019 Jul 30; 8: e45061.
[3]
Fruitwala S, El-Naccache DW, Chang TL. Multifaceted immune functions of human defensins and underlying mechanisms. Semin Cell Dev Biol. 2019 Apr; 88: 163-172.
[4]
Cheng, H. Y., Ning, M. X., Chen, D. K., & Ma, W. T. (2019). Interactions Between the Gut Microbiota and the Host Innate Immune Response Against Pathogens. Frontiers in immunology, 10, 607.
[5]
Kurchenko A. I., Beniuk VO, Potebnya GP, Kobis V. L., Tatskyi O. F., Neimark S. O. The role of exogenous peptides in the renewal of a full immune reaction in the conditions of the second immunodeficiency. Women's health. 2017; №1 (117). - P. 89-97.
[6]
Shypulin V, Stoliarova O, Konovalenko V, Tatskyy O, Didenko G, Konovalenko S. Study of the Exogenous Peptide Effect on the TGF-β1 Expression-A Risk Factor for the Hepatocellular Carcinoma Recurrence. American Journal of Biomedical and Life Sciences. Vol. 7, No. 4, 2019, pp. 73-78.
[7]
Litvinenko O. O, Tatskiy O. F, Konovalenko V. F, et al. Breast Cancer Relapse Prevention: Role of Anti-Relapsing Immunocorrection. Cancer Sci Res. 2019; 2 (2); 1-6.
[8]
Sachse K, Laroucau K, Riege K, Wehner S, Dilcher M, Creasy HH, Weidmann M, Myers G, Vorimore F, Vicari N, et al. Evidence for the existence of two new members of the family Chlamydiaceae and proposal of Chlamydia avium sp. nov. And Chlamydia gallinacea sp. nov. Syst Appl Microbiol 2014; 37: 79–88.
[9]
Williamson A. L. Chattopadhyay K., Hazra A., Dandara C. The combined risks ofreduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC Cancer. 2015; 15: 680.
[10]
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136: 189–197.
[11]
D. Wohlmeister, D. Barreto Vianna, Vi. Etges Helfer, F. Gimenes, M. Lopes Consolaro, R. Bones Barcellos, M. L. Rossetti, L. Calil, A. Buffon, D. A. Pilger. Association of human papillomavirus and Chlamydia trachomatis with intraepithelial alterations in cervix samples. Mem Inst Oswaldo Cruz. 2016 Feb; 111 (2): 106–113.
[12]
Melnikov SM, Tatskyi O. F. A new look at endometriosis: the role of restoring of full immune surveillance over ectopic cells of the endometrium. Women's health. 2017; № 7 (123). - P. 99-107.
[13]
Hou XX, Wang XQ, Li DJ. Roles of regulatory T Cells in pathogenesis of endometriosis. Reprod Dev Med 2019; 3: 117-23.
[14]
Yang S, Wang H, Li D, Li M. Role of Endometrial Autophagy in Physiological and Pathophysiological Processes. J Cancer. 2019 Jun 9; 10 (15): 3459-3471.
[15]
Vallvé-Juanico J, Houshdaran S, Giudice LC. The endometrial immune environment of women with endometriosis. Hum Reprod Update. 2019 Sep 11; 25 (5): 564-591.
[16]
Gorpinchenko I. I., Migov V. G. Treatment of patients with chronic calculous prostatitis using a peptide biostimulator Prostatilen: first results and prospects // Men's Health. - No 2 (45) 2013. - P. 37–40.
[17]
Zaseda Y. I., Solomenny RI, Ganushchak A. V. The experience of radical conservative treatment of chronic calculous-fibrous and fibrous-calculous prostatitis // Ukrainian journal "Healthy, gender and psychosomatic medicine." - 2016.-- No. 1 (03). - P. 34–43.
[18]
Zaseda Y. I., Tatskyi O. F. The effect of tissue accumulation of exogenous peptides is the key to understanding the mechanisms of harmonization of the immune homeostasis of patients with chronic bacterial prostatitis. Health of the man. 2017. № №1 (60). - P. 51 - 56.
[19]
Podpriatov S, Apostolov V, Tatskyy O, Konovalenko S. Konovalenko V. Аngioprotective properties of exogenous peptides. Practitioner №1 (8)-2019; 20-24.
Browse journals by subject